Monday, March 5, 2012

Slow, costly process stymies generic biotech drugs

One of the pledges of the Obama administration's healthcare overhaul was to enable cheaper copies of expensive biotech drugs, but the savings may not be as deep or come as quickly as hoped.

No comments:

Post a Comment

If you have a comment regarding the post above, please feel free to leave it here.